|Day Low/High||135.00 / 137.14|
|52 Wk Low/High||108.50 / 194.73|
Jim Cramer looks for domestic stocks he thinks will benefit from lower taxes and deregulation in the Trump era.
Jim Cramer says the future doesn't look healthy for Fitbit, but he's bullish on Xilinx and T-Mobile.
CoLucid Pharmaceuticals saw shares boost 32% ahead of the market open Wednesday.
The negative investor sentiment for health care stocks in 2016 presented a particularly challenging environment to accomplish anything well. Each of these CEOs met the challenge and succeeded.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CSWC, FNV, INTT, SCHL, VSAT Downgrades: AE, ASH, CNTY, CVV, HCOM, JAZZ, JLL, KND, MAC, MGNX, NS, OLED, OLP, SCSC, SEAS, TGH, XNCR Initiations: ABTX Read on to get TheStreet Quant Ratings' detailed report:
Jazz Pharmaceuticals's third-quarter results missed analysts' projections.
But we could see more volatility in the market.
While the public seized on Mylan's price increases for EpiPens, the story of a common drug industry practice - increasing prices ahead of generics entering the market - got lost.
Jazz Pharmaceuticals (JAZZ) reported lower earnings and revenue for the 2016 second quarter and gave an outlook below Wall Street's expectations.
Add-On Payment to Provide Additional Medicare Reimbursement for Defitelio and to Support Patient Access in the Inpatient PPS Hospital Setting
TheStreet highlights 3 stocks pushing the health care sector higher today.
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
Jazz Pharma (JAZZ) stock coverage was started with an ‘outperform’ rating and $190 price target at BMO Capital.